Payment overview · 2025
General Payments
$147.72
7 reported records · 6 companies
Healthcare provider profile · identity verified
Harley Hendrix, MD
Allopathic & Osteopathic Physicians|Family Medicine · PEMBROKE, GA · NPI 1003265836
Verified facts
What the public records show
CMS Open Payments records show Harley Hendrix, MD received $147.72 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.90 | 25.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.98 | 23.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.44 | 16.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.45 | 13.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.46 | 11.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.49 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.72 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
307 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 792 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 526 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 110 |
| Losartan Potassium | Losartan Potassium | 484 | 105 |
| Gabapentin | Gabapentin | 383 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 316 | 80 |
| Ozempic | Semaglutide | 307 | 55 |
| Omeprazole | Omeprazole | 288 | 62 |
| Famotidine | Famotidine | 263 | 57 |
| Metformin Hcl | Metformin Hcl | 244 | 67 |
| Potassium Chloride | Potassium Chloride | 240 | 63 |
| Lisinopril | Lisinopril | 235 | 57 |
| Furosemide | Furosemide | 229 | 64 |
| Carvedilol | Carvedilol | 227 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 37 |
| Trazodone Hcl | Trazodone Hcl | 172 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 35 |
| Sertraline Hcl | Sertraline Hcl | 136 | 24 |
| Tramadol Hcl | Tramadol Hcl | 134 | 29 |
| Buspirone Hcl | Buspirone Hcl | 132 | 27 |
| Alendronate Sodium | Alendronate Sodium | 125 | 34 |
| Lovastatin | Lovastatin | 119 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 27 |
| Mirtazapine | Mirtazapine | 114 | 28 |
| Jardiance | Empagliflozin | 112 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 35 |
| Alprazolam | Alprazolam | 109 | 17 |
| Montelukast Sodium | Montelukast Sodium | 104 | 27 |
| Eliquis | Apixaban | 99 | 16 |
| Allopurinol | Allopurinol | 97 | 23 |
| Simvastatin | Simvastatin | 96 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 20 |
| Glipizide | Glipizide | 88 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 12 |
| Meloxicam | Meloxicam | 84 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 16 |
| Lorazepam | Lorazepam | 75 | 15 |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Atenolol | Atenolol | 72 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | suppressed |
| Clonazepam | Clonazepam | 70 | 11 |
| Glipizide Er | Glipizide | 65 | 12 |
| Finasteride | Finasteride | 63 | suppressed |
| Baclofen | Baclofen | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Pregabalin | Pregabalin | 61 | 12 |
| Promethazine Hcl | Promethazine Hcl | 60 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Ezetimibe | Ezetimibe | 47 | 11 |
| Prednisone | Prednisone | 46 | 32 |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Colchicine | Colchicine | 33 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 26 |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 23 |
| Fluconazole | Fluconazole | 27 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 14 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Cosentyx (2 Syringes) | Secukinumab | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.72 · 7 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, PREVNAR 20 | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error